Eli Lilly has reported that Reyvow (lasmiditan) C-V, a tablet for migraine, helped patients to be pain-free at 60 minutes and up to 48 hours in the Phase III CENTURION clinical trial.

The drug is designed to strongly attach to 5-HT1F receptors located centrally and peripherally. This is said to be the first and only 5-HT1F receptor agonist approved by the US Food and Drug Administration (FDA).

Data showed that participants on the 100mg or 200mg dose of the drug had 3.8 and 4.6 times better chances of experiencing migraine pain freedom at two hours when compared to placebo.

In the trial, which was conducted in 1,471 adults with migraine, Reyvow was found to be superior over placebo in all gated endpoints, including pain relief at one hour and two hours, as well as sustained pain freedom at 24 hours.

The study analysed Reyvow’s efficacy and safety in treating migraine in adults, with or without aura, across four attacks.

In terms of pain relief, two-thirds of participants reported relief at two hours, representing 65.2% and 65.4% of patients treated with a 200mg and 100mg dose, respectively, compared to 41.3% in the placebo arm.

At 60 minutes, nearly 50% of patients on Reyvow experienced pain relief versus 29.3% on placebo. Data also revealed that one in five patients reported that their migraine did not interfere with daily activities two hours after treatment.

Nearly three times the participants who experienced ineffective, intolerable or became contraindicated in treatment with triptans for migraine attacks were noted to be pain-free on Lilly’s drug at two hours.

Eli Lilly pain and neurodegeneration vice-president Mark Mintun said: “We are delighted that Reyvow met all 18 patient-centric endpoints.

“These new clinical insights into Reyvow’s efficacy should enable healthcare providers to have more meaningful conversations with people with migraine who seek freedom from their painful attacks.”

Last month, Lilly, in alliance with the US National Institute of Allergy and Infectious Diseases (NIAID), launched the Phase III BLAZE-2 trial of LY-CoV555 to prevent Covid-19 in residents and staff at long-term care facilities.